Drawn from the experiences of the BaseCase Consulting Team, this is the introduction to ‘Succeeding in Value Communication’. This series of blog articles examines the key success factors in creating customer engagement tools that effectively communicate the clinical value and economic benefits of pharmaceuticals, medical devices, and diagnostic tests. How do you communicate the value … Continued
2021 年 9 月 14 日 – 11:00 am ET Securing reimbursement from national payers is critical to your product’s commercial success. However, payers at the local and regional levels continue to get more authority to manage their own budgets. This makes engaging with payers and designing an effective strategy for value communication difficult as the concept of … Continued
Developing interactive and easy-to-use stakeholder engagement content market access, medical affairs, and sales field teams is a time-consuming, expensive, and often decentralized process. BaseCase is “no-code” platform that enables you to visualize large complex datasets and economic models, which demonstrates the value of products to key decision-makers.
Major Release to Help Life Science Companies Maximize Go-to-Market Impact Princeton, N.J., 2021 年 7 月 8 日. Certara, a global leader in biosimulation, today announced the release of BaseCase software version 2021.06, which updates the value communication software platform to include new capabilities that can provide biopharmaceutical and medical device companies greater commercial success for new therapies … Continued
This blog post includes key takeaways from the opening session of Certara’s first Strategic Evidence and Value Communications Symposium. This session featured the following four speakers: Shawn W. Bates is vice president of US sales and business development, Maximilian Vargas is senior director of US access strategy and account management, and Alex Solis is a … Continued
Evidence & Access – Google Podcasts (Ep. 1-3) Welcome to the Market Access Radar Podcast, your expert briefing on the latest in Market Access and Health Economics in the Bio-Pharmaceutical Industries.
